Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 8, Issue 1, 2003, Pages 9-15

  Sharma, Sanjiv ^a   Bhambi, Brijesh ^a   Nyitray, William ^a   Desai, Kirit ^a   Davis, Dean L ^b,c   Sharma, Geetanjali ^d   Shukla, Pankaj ^b   File, Carla ^a   Ishimori, Tetsuo ^a  

^a Central Cardiology Medical Clinic   (United States)

^b Bakersfield Heart Hospital   (United States)

^c Florence Wheeler Cancer Center   (United States)

^d KERN MEDICAL CENTER   (United States)

Author keywords

Acute closure; Bivalirudin (Angiomax); Intracoronary brachytherapy; Intracoronary thrombus; Vascular brachytherapy

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; GLYCERYL TRINITRATE; HIRULOG; THROMBIN; VERAPAMIL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BRACHYTHERAPY; CASE REPORT; DISEASE PREDISPOSITION; FEMALE; HEMOSTASIS; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBUS;

EID: 0037347824     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840300800i103     Document Type: Article

References (13)

1. Teirstein PS, Massulo V, Jani S, et al. Catheter based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 336:1697-1703, 1997
2. Verin V, Urban P, Popowski Y, et al. Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study. Circulation 95:1138-1144, 1997
3. King SB, Williams DO, Chougule P, et al. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty. Circulation 97:2025-2030, 1998
4. Waksman R, Bhargava B, Mintz GS, et al. Late total occlusion after intracoronary brachytherapy for patients with instent restenosis. J Am Coll Cardiol 36:65-68, 2000
5. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy. Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 102:951-958, 2000
6. The Medicines Company: Important Medical Information. Angiomax is not recommended for use in patients undergoing brachytherapy; May 13, 2002
7. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother 36:1028-1041, 2002
8. Antman EM, Giugliano RP, Gibson M, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Ciriculation 99:2720-2732, 1999
9. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 30:1729-1734, 1997
10. Bamess GW, Buller C, Ohman EM, et al. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. Am Heart J 139:824-829, 2000
11. Bailey SR, O'Leary E, Chilton R. Angioscopic evaluation of site specific administration of ReoPro. Catheter Cardiovasc Diagn 42:181-184, 1997
12. Deng G, Royle G, Seiffert D, Loskutoff DJ. The PAI-1/vitronectin interaction: Two cats in a bag? Thromb Haemost 74:66-70, 1995
13. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in-vitro preformed platelet rich clots by abciximab increases fibrin exposure and fibrinolysis. Arterioscler Thromb Vasc Biol 21:142-148, 2001